Vitamin D and its Possible Relationship to Neuroprotection in COVID-19: Evidence in the Literature.


Journal

Current topics in medicinal chemistry
ISSN: 1873-4294
Titre abrégé: Curr Top Med Chem
Pays: United Arab Emirates
ID NLM: 101119673

Informations de publication

Date de publication:
2022
Historique:
received: 25 09 2021
revised: 30 01 2022
accepted: 03 02 2022
pubmed: 4 4 2022
medline: 19 8 2022
entrez: 3 4 2022
Statut: ppublish

Résumé

Vitamin D is a hormone involved in the regulation of important biological processes such as signal transduction, immune response, metabolic regulation and also in the nervous and vascular systems. To date, coronavirus disease 2019 (COVID-19) infection does not have a specific treatment. However, various drugs have been proposed, including those that attenuate the intense inflammatory response, and recently, the use of vitamin D, in clinical trials, as part of the treatment of COVID-19 has provided promising results. It has been observed in some clinical studies that the use of cholecalciferol (vitamin D3) and its two metabolites the circulating form, calcidiol or calcifediol (25-hydroxycalciferol, 25-(OH)-D), and the active form, calcitriol (1,25-(OH)2-D), in different doses, improve the clinical manifestations, prognosis, and survival of patients infected with COVID-19 probably because of its anti-inflammatory, antiviral and lung-protective action. In relation to the central nervous system (CNS) it has been shown, in clinical studies, that vitamin D is beneficial in some neurological and psychiatric conditions because of its anti-inflammatory and antioxidant properties, modulation of neurotransmitters actions, and regulation of calcium homeostasis between other mechanisms. It has been shown that COVID-19 infection induces CNS complications such as headache, anosmia, ageusia, neuropathy, encephalitis, stroke, thrombosis, cerebral hemorrhages, cytotoxic lesions, and psychiatric conditions and it has been proposed that the use of dietary supplements, as vitamin and minerals, can be adjuvants in this disease. In this review, the evidence of the possible role of vitamin D, and its metabolites, as a protector against the neurological manifestations of COVID-19 was summarized.

Identifiants

pubmed: 35366776
pii: CTMC-EPUB-122160
doi: 10.2174/1568026622666220401140737
doi:

Substances chimiques

Vitamins 0
Vitamin D 1406-16-2
Cholecalciferol 1C6V77QF41
Calcifediol P6YZ13C99Q

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1346-1368

Subventions

Organisme : Hospital Central Militar, SEDENA
ID : 068/2021

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Saray Quintero-Fabián (S)

Laboratorio de Medicina Traslacional, Escuela Militar de Graduados de Sanidad, UDEFA, Mexico City, 11200, Mexico.

Cindy Bandala (C)

Division de Neurociencias, Instituto Nacional de Rehabilitación, Secretaría de Salud, Mexico City, 14389, Mexico.
Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, 11340, Mexico.

Luz Adriana Pichardo-Macías (LA)

Departamento de Fisiología, Instituto Politécnico Nacional, Escuela Nacional de Ciencias Biológicas, Mexico City, 07738, Mexico.

Itzel Jatziri Contreras-García (IJ)

Laboratorio de Fisiología, Escuela Militar de Graduados de Sanidad, UDEFA, Mexico City, 11200, Mexico.

Saúl Gómez-Manzo (S)

Laboratorio de Bioquímica Genética, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City, 04530, Mexico.

Beatriz Hernández-Ochoa (B)

Laboratorio de Inmunoquímica, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Mexico City, 06720, Mexico.

José Arturo Martínez-Orozco (JA)

Departmento de Infectología, Instituto Nacional de Enfermedades Respiratorias, Ismael Cosío Villegas, Secretaría de Salud, Mexico City, 14080, Mexico.

Iván Ignacio-Mejía (I)

Laboratorio de Medicina Traslacional, Escuela Militar de Graduados de Sanidad, UDEFA, Mexico City, 11200, Mexico.

Noemí Cárdenas-Rodríguez (N)

Laboratorio de Neurociencias, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City, 04530, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH